Scarica l'app Stockscreener
16.17
0.25%
0.04
Lb Pharmaceuticals Inc Borsa (LBRX) Ultime notizie
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
LB Pharmaceuticals Inc Rings the Closing Bell - Nasdaq
LB Pharmaceuticals Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Novo-Backed MapLight Raises $258.9 Million in US IPO, Placement - Bloomberg.com
LB Pharmaceuticals Inc (LBRX) Recent Insider Transactions - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Latest Press Releases & Corporate News - Yahoo
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo! Finance Australia
Anna Eramo Net Worth (2025) - GuruFocus
Rebecca Luse Net Worth (2025) - GuruFocus
Zachary Prensky Net Worth (2025) - GuruFocus
LB Pharmaceuticals appoints Rawls as SVP of Regulatory Affairs - MSN
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs - GlobeNewswire
LB Pharmaceuticals appoints James Rawls as SVP of regulatory affairs By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Inc Appoints James Rawls as Senior Vice President of Regulatory Affairs - MarketScreener
LB Pharmaceuticals appoints James Rawls as SVP of regulatory affairs - Investing.com
LB Pharmaceuticals Inc's Quiet Period Set To End on October 21st (NASDAQ:LBRX) - MarketBeat
LB Pharmaceuticals Inc’s Quiet Period Set To End on October 21st (NASDAQ:LBRX) - Defense World
Analysts Set LB Pharmaceuticals Inc (NASDAQ:LBRX) PT at $30.50 - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Raised to Hold at Zacks Research - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Biopharma financings climb to $18.7B in the third quarter - BioWorld MedTech
Q3 Earnings Forecast for LBRX Issued By Leerink Partnrs - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Leerink Partnrs - Defense World
September biopharma financings jump 54% to $7.12B - BioWorld MedTech
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded at Leerink Partnrs - MarketBeat
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms - Sahm
Drug developer MapLight eyes $704.3 million valuation in US IPO - Reuters
LB Pharmaceuticals to Present Three Posters at 38th ECNP - GlobeNewswire
Leerink Partners Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $34 - 富途牛牛
Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential - TipRanks
Leerink Partners Initiates LB Pharmaceuticals at Outperform With $34 Price Target - MarketScreener
0.66 effect size in cognition: LB Pharma's LB‑102 shows dose‑dependent gains; 3 ECNP posters Oct 11-14 - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Now Covered by Analysts at Leerink Partners - MarketBeat
LB Pharmaceuticals stock initiated at Outperform by Leerink Partners - Investing.com
Promising Prospects for LB Pharmaceuticals: Buy Rating Affirmed on LB-102’s Market Potential - TipRanks
Piper Sandler initiates coverage on LB Pharmaceuticals stock with Overweight rating - Investing.com
Stifel initiates coverage on LB Pharmaceuticals stock with Buy rating - Investing.com
LB Pharmaceuticals IncCommon Stock (Nasdaq:LBRX) Stock Quote - FinancialContent
LB Pharmaceuticals Appoints William Kane and Rekha Hemrajani To Board - citybiz
LB Pharmaceuticals adds two directors following Nasdaq debut By Investing.com - Investing.com Nigeria
LB Pharmaceuticals adds two directors following Nasdaq debut - Investing.com India
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani - The Manila Times
Strategic Board Expansion: LB Pharmaceuticals Strengthens Leadership for Phase 3 Schizophrenia Drug Trial - Stock Titan
Scoop: Voltron Therapeutics plans IPO next year - Axios
Deep Track Capital, LP Acquires Significant Stake in LB Pharmaceuticals Inc - GuruFocus
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pha - GuruFocus
COMMODORE CAPITAL LP Acquires 1,225,000 Shares in LB Pharmaceuti - GuruFocus
Deep Track Capital, LP Acquires Significant Stake in LB Pharmace - GuruFocus
0.64%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):